BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
BeOne Medicines Ltd ADR ONC
News
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines
BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5
Chinese Biopharma Stocks Rally as Investors Favor Healthcare Over AI
BeOne Medicines Gets FDA Accelerated Approval for Lymphoma Drug
BeOne Medicines Shares Surge After Robust First-Quarter
BeOne Medicines Lymphoma Drug Gets FDA Priority Review
Zymeworks, Jazz Pharmaceuticals Shares Rise Following Positive Phase 3 Results for Cancer Treatment
BeOne Medicines Gets Breakthrough Therapy Designation for Sonrotoclax
United States